Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2024-09-12 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a detailed disclosure report about changes in issued shares and treasury shares of a listed company, including share issuance under employee share plans and share repurchases. It references specific Hong Kong Stock Exchange Listing Rules (Main Board and GEM) sections 13.25A, 17.27A, 10.06(4)(a), and others, which govern disclosure of share capital changes. The document includes tables showing share counts before and after events, prices, and confirmations of compliance with listing rules. It is not a full financial report, earnings release, or management discussion, but a regulatory disclosure about share capital changes. The document length is about 4046 characters, which is substantive and contains detailed data, not just an announcement of a report. Therefore, it fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2024-09-12 Chinese
港股公告：员工购股计划项下的股份购买
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding the purchase of shares under an employee stock purchase plan (2018 Employee Stock Purchase Plan) by eligible employees. It provides details such as the number of shares purchased, purchase price, participation numbers, and the rationale behind the plan. The document references compliance with listing rules and provides specific dates and figures related to the stock purchase period. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a report like an Annual Report or Interim Report, nor is it a call transcript or management report. It is an announcement about share purchases under an employee plan, which fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories like Director's Dealing or Share Issue/Capital Change (since it is about employee stock purchase plan shares, not new share issuance or buybacks). The document length is short (2086 characters), and it is a standalone announcement rather than a report or presentation.
2024-09-11 Chinese
港股公告：员工购股计划
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the 2018 Employee Stock Purchase Plan (ESPP) for BeiGene, Ltd., detailing the subscription period, eligibility, purchase price, and other plan terms. It references compliance with listing rules and provides specifics about the plan's operation and participant numbers. There are no financial statements, quarterly or annual results, nor is this a transcript or management discussion. The document is a formal announcement about a capital-related employee share purchase plan, which fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive details about the plan rather than just a notice of report publication, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2024-09-08 Chinese
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 100% confidence The document is a monthly securities movement report for BeiGene, Ltd. as submitted to the Hong Kong Stock Exchange. It details changes in registered capital, issued shares, stock options, and other share-related movements for the month ending August 31, 2024. The document includes confirmations required under the Hong Kong Listing Rules and is structured as a regulatory compliance report on share capital changes. It does not contain financial statements, earnings data, management discussion, or audit information. It is not an announcement of a report publication but a substantive monthly report on share capital changes. This fits the definition of a Share Issue/Capital Change (SHA) filing, which covers announcements regarding new share issues, stock splits, or other capital changes.
2024-09-05 Chinese
港股公告：授出购股权及受限制股份单位
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding the grant of share options and restricted stock units under the company's 2016 Stock Option and Incentive Plan. It details the number of shares/options granted, exercise prices, vesting schedules, and related terms. The document references compliance with listing rules and provides definitions related to the stock plan. It is not a full financial report, earnings release, or management discussion. It is also not a proxy statement or AGM material. The document is a regulatory announcement about share-based compensation grants to employees, which fits the category of Regulatory Filings (RNS) as it does not fit other more specific categories and is a compliance disclosure under listing rules. The document length is under 5,000 characters and is a standalone announcement, not a report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2024-09-05 Chinese
港股公告：翌日披露报表
Transaction in Own Shares Classification · 95% confidence The document is a detailed disclosure report about changes in issued shares, treasury shares, share repurchases, and sales of treasury shares by the company. It references specific Hong Kong Stock Exchange Listing Rules (Main Board and GEM) such as Rule 13.25A and 17.27A, which govern disclosure of share capital changes. The document includes tables showing share issuance events, share counts before and after events, prices per share, and confirmations of compliance with regulatory requirements. It is not an annual or quarterly financial report, nor an earnings release or management discussion. It is not a proxy statement, AGM material, or legal proceeding. The document is a regulatory disclosure specifically about share capital changes and share repurchases. This fits the definition of "Transaction in Own Shares (POS)" which covers reports of the company buying back or selling its own shares. The document is substantive and detailed, not a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is POS with high confidence.
2024-09-02 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.